| Abstract: | Unique among developed countries in denying patent protection for pharmaceuticals, Canada modified her laws in 1987 and again in 1993 to meet international standards, thereby permitting her to participate in NAFTA and become a signatory of the TRIPS of the Uruguay Round. Canada's concerns for containing health costs and providing quality health care for all its citizens were important factors in her original position. It was only as a result of international pressure and an alliance between the multinational pharmaceutical firms and the university community in Canada that she offered greater patent protection. The results of these changes had an immediate effect on improving the business environments and significant investments by the multinational pharmaceutical firms have increased substantially since 1987. |
